Who Paid My Doc
Michael Binder
Adult Congenital Heart Disease Minneapolis, MN Medical Doctor
NPI 1750872297 CMS profile 9152635
Po Box 860912, Minneapolis, MN 55486
General payments
$282
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Michael Binder of Minneapolis, MN is reported in the CMS Open Payments database as having received $282 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $36 | 2 | |
| 2022 | General | $246 | 3 |
Beside peers
- Michael Binder
- Adult Congenital Heart Disease median
- Middle half of Adult Congenital Heart Disease
- National median
In program year 2025, general payments to Michael Binder were reported at $0. Among 56 Adult Congenital Heart Disease profiles paid that year, the median was $272 and the middle half received between $51 and $642.
Show as a table
| Year | Michael Binder | Adult Congenital Heart Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $202 | $71–$498 | $163 |
| 2020 | $0 | $127 | $28–$236 | $114 |
| 2021 | $0 | $138 | $34–$310 | $132 |
| 2022 | $246 | $275 | $125–$1,572 | $149 |
| 2023 | $0 | $215 | $58–$1,454 | $160 |
| 2024 | $36 | $273 | $84–$801 | $164 |
| 2025 | $0 | $272 | $51–$642 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
333
Drug cost
$101,488
Branded share of claims
28.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 56 | $58,140 | |
| Jardiance Empagliflozin | Brand | 15 | $21,173 | |
| Entresto Sacubitril/Valsartan | Brand | 12 | $20,100 | |
| Metoprolol Succinate | Generic | 73 | $743 | |
| Atorvastatin Calcium | Generic | 29 | $261 | |
| Sotalol Sotalol Hcl | Brand | 11 | $184 | |
| Rosuvastatin Calcium | Generic | 24 | $184 | |
| Carvedilol | Generic | 13 | $177 | |
| Amlodipine Besylate | Generic | 25 | $145 | |
| Furosemide | Generic | 31 | $132 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Congenital Heart Disease in Minnesota
Related records
Adult Congenital Heart Disease in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Adult Congenital Heart Disease
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.